Kwangdong Phar (009290) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kwangdong Phar (009290) has a cash flow conversion efficiency ratio of -0.015x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-10.75 Billion ≈ $-7.29 Million USD) by net assets (₩712.31 Billion ≈ $482.72 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Kwangdong Phar market capitalisation for the company's overall valuation and market capitalisation.
Kwangdong Phar - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Kwangdong Phar's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Kwangdong Phar Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kwangdong Phar ranked by their cash flow conversion efficiency. Explore 009290 cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Utah Medical Products Inc
NASDAQ:UTMD
|
0.026x |
|
Hudson Technologies Inc
NASDAQ:HDSN
|
0.028x |
|
Rhom Bho Property Public Company Limited
BK:TITLE
|
-0.254x |
|
Shin Yang Shipping Corporation Bhd
KLSE:5173
|
0.009x |
|
ST George Mining Ltd
AU:SGQ
|
-0.089x |
|
Kaltura Inc
NASDAQ:KLTR
|
-1.154x |
|
BAJEL PROJECTS LTD
NSE:BAJEL
|
0.009x |
|
Shenzhen Dvision Video Communica
SHE:300167
|
-0.220x |
Annual Cash Flow Conversion Efficiency for Kwangdong Phar (2011–2025)
The table below shows the annual cash flow conversion efficiency of Kwangdong Phar from 2011 to 2025. View Kwangdong Phar stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩711.80 Billion ≈ $482.37 Million |
₩82.34 Billion ≈ $55.80 Million |
0.116x | +688.50% |
| 2024-12-31 | ₩618.27 Billion ≈ $418.99 Million |
₩-12.15 Billion ≈ $-8.24 Million |
-0.020x | +1.46% |
| 2023-12-31 | ₩588.05 Billion ≈ $398.51 Million |
₩-11.73 Billion ≈ $-7.95 Million |
-0.020x | -117.37% |
| 2022-12-31 | ₩547.05 Billion ≈ $370.73 Million |
₩62.82 Billion ≈ $42.57 Million |
0.115x | +10.21% |
| 2021-12-31 | ₩527.24 Billion ≈ $357.31 Million |
₩54.94 Billion ≈ $37.23 Million |
0.104x | +129.22% |
| 2020-12-31 | ₩502.18 Billion ≈ $340.32 Million |
₩22.83 Billion ≈ $15.47 Million |
0.045x | -30.54% |
| 2019-12-31 | ₩447.46 Billion ≈ $303.24 Million |
₩29.29 Billion ≈ $19.85 Million |
0.065x | -46.89% |
| 2018-12-31 | ₩430.84 Billion ≈ $291.97 Million |
₩53.10 Billion ≈ $35.98 Million |
0.123x | +118.65% |
| 2017-12-31 | ₩416.30 Billion ≈ $282.12 Million |
₩23.46 Billion ≈ $15.90 Million |
0.056x | -21.78% |
| 2016-12-31 | ₩399.68 Billion ≈ $270.86 Million |
₩28.80 Billion ≈ $19.52 Million |
0.072x | -33.84% |
| 2015-12-31 | ₩377.73 Billion ≈ $255.98 Million |
₩41.14 Billion ≈ $27.88 Million |
0.109x | +4.55% |
| 2014-12-31 | ₩314.40 Billion ≈ $213.06 Million |
₩32.75 Billion ≈ $22.19 Million |
0.104x | -11.92% |
| 2013-12-31 | ₩290.82 Billion ≈ $197.09 Million |
₩34.39 Billion ≈ $23.31 Million |
0.118x | +33.16% |
| 2012-12-31 | ₩267.27 Billion ≈ $181.13 Million |
₩23.74 Billion ≈ $16.09 Million |
0.089x | -19.93% |
| 2011-12-31 | ₩249.52 Billion ≈ $169.09 Million |
₩27.68 Billion ≈ $18.76 Million |
0.111x | -- |
About Kwangdong Phar
Kwang Dong Pharmaceutical Co., Ltd. operates as a human healthcare provider in South Korea. It develops and sells OTC drugs in the areas of ophthalmic, mineral preparations, nutritious tonics, antipyretic, analgesic, anti inflammatory agents, circulating system, and vitamins; and ETC drugs in the areas of anti-malignant-tumor agent, obesity drug, appetite suppressant, antipyretic, analgesic, anti… Read more